Anti-cancer strategies using RCDs work by targeting genes involved in cancer differentiation, growth, and proliferation, such as Bcl-2 [103], survivin [104], early growth response protein 1 (EGR1) [105], and urokinase plasminogen activator surface receptor (uPAR) [106], or genes involved in cancer survival, such as PD-L1 [107], c-jun [108], and insulin-like growth factor II promoter 3 (IGF-IIP3) [109]. Here, EGR1 is linked to cancer.